Differences in Glucose Tolerance Between Fixed-Dose Antihypertensive Drug Combinations in People With Metabolic Syndrome
Response to O'Malley, Bouldin, and Riche
- George L. Bakris, MD
- From the Hypertension Unit, Section of Endocrinology, Diabetes, and Metabolism, Pritzker School of Medicine, University of Chicago, Chicago, Illinois
- Address correspondence to George Bakris, MD, Professor of Medicine, Director, Hypertension Unit, Section of Endocrinology, Diabetes & Metabolism, University of Chicago-Pritzker School of Medicine, Chicago, IL 60637. E-mail: gbakris{at}earthlink.net
Unfortunately, O'Malley, Bouldin, and Riche (1) are laboring under the impression that the peroxisome proliferator–activated receptor-γ (PPARγ) effects, described for some angiotensin receptor blockers (ARBs), such as telmisartan, in animal and cell models, are clinically relevant (2–4); sadly, this is not the case. The authors anchor their argument on data that evaluated telmisartan on PPARγ activity but unfortunately had no comparator ARB (5). Moreover, there are no …
